{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-25-013040","form_type":"8-K","ticker":"KAPA","cik":"0001962011","company_name":"Kairos Pharma, LTD.","filed_at":"2025-09-11T23:59:59+00:00","discovered_at":"2026-05-14T18:02:45.708778+00:00","generated_at":"2026-05-17T06:54:48.840086+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Kairos Pharma to host KOL event Sept 18 for ENV105 Phase 2 interim efficacy data","bullets":["Virtual KOL event on Sept 18, 2025, at 5 p.m. ET to discuss interim efficacy results from ENV105 Phase 2 trial in advanced prostate cancer.","ENV105 is a first-in-class CD105 antagonist; interim safety analysis (July 2025) showed well-tolerated with no dose-limiting toxicities or Grade 3/4 events.","Speakers include principal investigators Drs. Bhowmick, Swami, Lee, and Posadas.","ENV105 targets CD105-driven drug resistance in castration-resistant prostate cancer; trial combines ENV105 with apalutamide."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-25-013040","json":"https://secwatch.observer/filing/0001493152-25-013040.json","markdown":"https://secwatch.observer/filing/0001493152-25-013040.md","text":"https://secwatch.observer/filing/0001493152-25-013040.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1962011/000149315225013040/0001493152-25-013040-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1962011/000149315225013040/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T06:54:48.840086+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}